Abstract
To date, there is not a validated method by which absorbed yttrium-90 (Y-90) by hepatic tumors and liver parenchyma can be calculated immediately following transarterial radioembolization (TARE). Instead, treatment response is measured using MRI or CT several weeks to months following treatment compared with pre-treatment baseline imaging. Although this evaluation is useful in the long-term management of patients with malignant hepatic disease, it delays the opportunity for immediate rectification in cases where radiation delivered to hepatic tumors was insufficient.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
